Navigation Links
Archivel Farma's TB Vaccine May Cut Treatment Time From Nine Months to One

BIO CONVENTION, CHICAGO, Illinois, May 5, 2010 /PRNewswire/ -- Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI(R) in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.

It has now been discovered that TB does not lie "dormant" but is actually waging a constant war with the host, constantly re-infecting the lungs. Provided that the host is healthy, it has the upper hand and usually keeps the TB in check - LTBI. TB is particularly tricky to eliminate as it can be either replicating, when it can be killed by the antibiotics, or non-replicating when antibiotics are useless. The long, nine month course of antibiotics is needed to ensure that all traces of the non-replicating form are eliminated from the lungs. Further details can be found at

Archivel's novel, two pronged approach combines a one month course of antibiotic to eliminate the bacteria in the replicating stage and two injections of the company's RUTI vaccine that stimulates the body's own immune system to fight the TB bacteria. This combination approach reduces the treatment time from nine months to one, is easier to manage, less expensive, more effective and more likely to be done completely. The company estimates that cost comparison between the current and new treatment, when allowing for all the logistical costs means that the new treatment costs around half that of the old treatment.

Further information at

Full details can be found in the accompanying press release AF004002 entitled "Archivel's RUTI, a novel therapeutic vaccine to Latent Tuberculosis, starts phase II clinical trials in South Africa" and press release AF004001 entitled "Major breakthrough in fight to eliminate Tuberculosis".

Further information on Archivel at

Archivel Farma S.L., 61 c/ Fogars de Tordera, Poligon Industrial Bonavista, 08916 BADALONA, Spain. Tel +34-93-497-2456, +34-637-057432,

Press information and illustrations

Nigel Robson, Vortex PR, Tel +44(0)1481-233080,

RUTI is a registered trademark of Archivel Farma S.L.

SOURCE Archivel Farma
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
4. Anthrax vaccine produces immunity with nanoparticles, not needles
5. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
6. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
7. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
8. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
9. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
10. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
11. New nanoparticle vaccine is more effective but less expensive
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
(Date:11/24/2015)...  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General ... a.m. Israel time, at the law offices of ... 36 th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election ... , approval of an amendment to certain terms of options granted to ...
Breaking Biology Technology:
(Date:11/11/2015)... Minn. , Nov. 11, 2015   MedNet Solutions ... entire spectrum of clinical research, is pleased to announce that ... in Clinical Trials (PCT) event, to be held November ... be able to view live demonstrations of iMedNet ... and learn how iMedNet has been able to ...
(Date:11/9/2015)... , Nov. 09, 2015 ... addition of the "Global Law Enforcement ... offering. --> ) has ... Law Enforcement Biometrics Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
Breaking Biology News(10 mins):